Business
Ozempic Maker Novo Nordisk’s Investors AreNervously Looking Into the Future
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.
This story summarizes reporting from The New York Times. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.
Read full story on The New York Times →Eshe Nelson1 Sept 2026, 05:09 pmUpdated 15h ago1 min readBusinessGlobal
Global — Eshe Nelson
